Vincent LoPriore is the Executive Chairman of the Board of Hepion Pharmaceuticals and became a Board member in March 2026. From April 2025 to July 2026, he served as a member of the Board of Directors of Canton Strategic Holdings, Inc. (Nasdaq: CNTN). Mr. LoPriore is a financial professional with over 30 years of experience in the investment banking industry. He began his career at Oppenheimer & Co. in 1989 and subsequently held senior positions at Legg Mason, Inc. and was a partner at C.E. Unterberg, Towbin, where he led the special equities group and completed more than $150 million in private placement transactions. Mr. LoPriore has served in leadership roles at various boutique and mid-sized investment firms, focusing on capital raising, regulatory navigation. Mr. LoPriore is currently a Partner and registered representative of President Street Global, LLC, a FINRA-registered broker-dealer. He also serves as the investment manager of the Gravitas Capital LP Fund, with a track record of strong investment performance. Mr. LoPriore has longstanding relationships within the biomedical industry and supports philanthropic initiatives including Race to Erase MS and Cure Addiction Now.
Sireesh Appajosyula became a member of the board of directors in March 2026 and is the Chief Executive Officer of Hepion Pharmaceuticals since August 2026. From its inception, he served as a board member and became the Chief Operating Officer in July 2023 and Chief Executive Officer in June 2025 of Tharimmune, Inc (Nasdaq: CNTN). He has also served as the interim Chief Financial Officer of Tharimmune from November to December 2026. He served as the Chief Executive Officer of Gravitas Life Sciences, Inc., a wholly owned subsidiary of Canton Strategic Holdings Inc. (Nasdaq: CNTN) until its acquisition by Hepion in October 2026. Previously, he served as SVP, Corporate Development and Operations of 9 Meters Biopharma, Inc., a biotechnology company. Prior to 9 Meters, he was at Salix Pharmaceuticals, Inc. in increasing roles of responsibility in medical affairs, product commercialization and business development, until the Company’s acquisition by Bausch Health (Nasdaq: BHC) in 2015. Prior to Salix, he was involved in various roles at Amgen Inc., Critical Therapeutics, Inc. and Sanofi (formerly Aventis). Dr. Appajosyula received his Bachelor of Science and Doctor of Pharmacy from Rutgers University.
Gary Stetz is the Chief Financial Officer of Hepion Pharmaceuticals and became a Board member in March 2026. From April 2025 to July 2026, he served as a member of the Board of Directors of Canton Strategic Holdings, Inc. (Nasdaq: CNTN). Mr. Stetz is a Certified Public Accountant with over 35 years of experience across accounting, finance, business valuation and corporate governance. He serves as Managing Partner of Stetz, Belgiovine, Manwarren and Wallis P.C., an accounting, auditing, tax compliance and advisory services firm with more than 1,000 corporate clients. Mr. Stetz’s leadership experience includes founding Allegiance Community Bank and serving on the Board of BCB Bancorp. He is co-author of the book Project Management Accounting: Budgeting, Tracking, and Reporting Costs and Profitability. He has earned multiple professional credentials, including Certified Mediator, Certified Fraud Examiner and Chartered Global Management Accountant.
Chase LoPriore became a member of the Board of Directors of Hepion Pharmaceuticals in March 2026. Until November 2025, he served as Chief of Staff of Tharimmune, Inc. (Nasdaq: CNTN) and currently serves as Director of Operations and Chief of Staff of Gravitas Life Sciences, LLC., a wholly owned subsidiary of Hepion. While at Tharimmune, Mr. LoPriore played a central role in the implementation of multiple transactions and supported the coordination of cross-functional execution across legal, finance, compliance and technology teams. Working with the CEO of Tharimmune, inc., Mr. LoPriore aligned operations through a multi-phase deal involving strategic repositioning of corporate assets including a digital framework that ultimately helped drive the transaction to a successful close on an accelerated timeline.
Bobbi Fox-Caminiti serves as Director of Operations at Hepion Pharmaceuticals, where she oversees the Company's day-to-day operations and supports the execution of key strategic initiatives. She is responsible for corporate operations, finance and administrative functions, human resources, investor administration, and board support, working closely with the executive leadership team to enhance operational efficiency and ensure effective execution across the organization. With more than 20 years of experience in business operations, executive management, and organizational leadership, Ms. Fox-Caminiti has a proven track record of improving operational efficiency, implementing scalable processes, and supporting the growth of both private and public organizations. Her leadership helps drive the Company's continued growth and operational excellence.
